CLMN

Across TCGA pan-cancer cohorts, CLMN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLMN data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CLMN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLMN expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BRCA, UCEC, and LIHC are the cancer types where CLMN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.136	0.579	<.001	28	view →
UCEC	DFS	Median	II,III,IV	0.922	0.435	.020	16	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
SKCM	DFS	Median	All	0.720	0.212	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CLMN–BRCA (OS)

Open the BRCA breakdown →